福田股份(08196.HK)盈警:預計中期淨虧損不少於80萬元
格隆匯8月16日丨福田股份(08196.HK)發佈公吿,集團預期收入將由截至2023年6月30日止六個月約人民幣6530萬元減少至截至2024年6月30日止六個月約人民幣1780萬元,導致截至2024年6月30日止六個月的淨虧損不少於約人民幣80萬元,比較截至2023年6月30日止六個月的淨利潤約人民幣850萬元。
董事會認為,收入減少及虧損主要由於(i)本期間客户對有關的工程、採購及建設項目的進度確認延期及(ii)集團于越南地區的現有項目上年度已完成,新項目亦預期於本年度下半年開始,故本期間未有錄得收入。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.